4basebio (LON:4BB) Trading Down 3.4% - Should You Sell?

Key Points

• 4basebio's share price fell 3.4%, closing at GBX 700 ($9.33) during Thursday's trading, with a significant increase in trading volume of 407% compared to its average session volume.
• Royal Bank of Canada maintains an "outperform" rating for 4basebio, projecting a price target of GBX 1,600, despite the company's recent earnings report showing a loss of GBX (50) per share.
• Insider Heikki Lanckriet purchased 2,000 shares at an average cost of GBX 749, indicating ongoing insider confidence in the company.

4basebio PLC (LON:4BB - Get Free Report)'s share price fell 3.4% during trading on Thursday . The company traded as low as GBX 700 ($9.33) and last traded at GBX 700 ($9.33). 5,934 shares were traded during mid-day trading, an increase of 407% from the average session volume of 1,170 shares. The stock had previously closed at GBX 725 ($9.66).

Wall Street Analysts Forecast Growth

Separately, Royal Bank Of Canada reissued an "outperform" rating and issued a GBX 1,600 target price on shares of 4basebio in a report on Thursday, October 2nd. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of GBX 1,600.

4basebio Stock Down 3.4%

The company has a fifty day simple moving average of GBX 811.30 and a 200-day simple moving average of GBX 968.80. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47. The firm has a market cap of £108.40 million, a P/E ratio of -7.07 and a beta of 1.09.

4basebio (LON:4BB - Get Free Report) last released its quarterly earnings results on Monday, September 29th. The company reported GBX (50) earnings per share (EPS) for the quarter. On average, equities analysts anticipate that 4basebio PLC will post -3.43 earnings per share for the current year.

Insider Activity at 4basebio

In other 4basebio news, insider Heikki Lanckriet acquired 2,000 shares of the stock in a transaction dated Monday, September 29th. The shares were acquired at an average cost of GBX 749 per share, for a total transaction of £14,980. 12.04% of the stock is owned by insiders.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.